Stein, Isidore; Katabi, Ghazi
May 1962
Angiology;May1962, Vol. 13 Issue 5, p212
Academic Journal
The article presents a discussion related to the use of a new diuretic polythiazide in congestive failure and hypertension. A. series of patients was studied to observe the effect of a new thiazide on their signs of congestive failure and another group with hypertension. Of 17 patients with congestive failure, 16 showed good or fair results. One patient was not helped. Eight of the patients with hypertension showed a definite lowering of their pressure. Four others who were also decompensated did well. It is concluded that polythiazide is a potent diuretic and hypotensive agent in doses of 2 to 4 mg a day, with no distressing side-effects.


Related Articles

  • Patterns of antihypertensive therapy in new users of angiotensin II-receptor blockers. Young, Christopher H.; Zhang, Kui; Poret, Amy W. // American Journal of Health-System Pharmacy;11/15/2005, Vol. 62 Issue 22, p2381 

    Purpose. The patterns of angiotensin II-receptor blocker (ARB) therapy in patients with and without a history of antihypertensive use were studied. Methods. Data for this retrospective cohort study were obtained from Caremark's data warehouse. Patients were included in the analysis if they...

  • ACETAZOLAMIDE ALONE AND IN COMBINATION WITH RESERPINE IN THE TREATMENT OF HYPERTENSION. Brest, Albert N.; Onesti, Gaddo; Sekine, George; Kodama, Ryuichi; Moyer, John H. // Angiology;Nov1961, Vol. 12 Issue 11, p589 

    Acetazolamide used alone produced a minor antihypertensive effect. Although the addition of reserpine enhanced the hypotensive response, the therapeutic combination of acetazolamide and reserpine appears to be less effective than combined thiazide-Rauwolfia regimens. The antihypertensive...

  • GUANETHIDINE AND HYPERTENSION AFTER FIVE YEARS. Leishman, A. W. D.; Oxon, D. M.; Sandler, G. // Angiology;Nov1967, Vol. 18 Issue 11, p705 

    The progress of 224 hypertensive patients (112 male; 112 female) treated with guanethidine for 1 to 5½ years is reported. The daily dose of guanethidine has varied from 10 to 200 mg. Fewer than half the patients have required a diuretic drug in addition. One third of the patients required a...

  • Renal and hemodynamic responses to bumetanide in hypertension: Effects of nitrendipine. Wilcox, Christopher S.; Loon, Nicholas R.; Ameer, Barbara; Limacher, Marian C. // Kidney International;Oct1989, Vol. 36 Issue 4, p719 

    The effects of a calcium antagonist on the response to a loop diuretic were tested in eight hypertensive patients while they received 120 mmol · 24 hr-1 of dietary Na. Nitrendipine (N; 20 mg) or placebo (P) was administered twice daily for five days and bumetanide (B; 1 mg i.v.) for the last...

  • Prescribing for uncomplicated hypertension. Cox, Bev // Practice Nurse;10/24/2008, Vol. 36 Issue 7, p25 

    The article explains the basic pathophysiology of raised blood pressure, and presents case studies to demonstrate how to effectively implement the guidelines in the treatment of patients with uncomplicated hypertension. In patients with hypertension who are over 55 years old, more initial...

  • Effect of Captopril on Plasma Prolactin in Patients with Essential Hypertension. Saito, Ikuo; Takeshita, Eiko; Hayashi, Satomi; Takenaka, Tunec; Murakami, Marohito; Saruta, Takao; Nagano, Shiro; Sekihara, Toshio // Angiology;May1990, Vol. 41 Issue 5, p377 

    The effects of the angiotensin-converting enzyme inhibitor captopril on blood pressure, heart rate, plasma prolactin, and renin activity were examined in a single-blind, placebo-controlled trial on 30 patients with essential hypertension (15 given drug, 15 placebo). Captopril, 25 mg administered...

  • Patients noncompliant with cardio meds within six months.  // Pharmaceutical Representative;Aug2005, Vol. 35 Issue 8, p11 

    Examines the ability of patients suffering from high blood pressure or high lipid levels to adherence to a drug regimen including both antihypertensive and lipid-lowering medications. Evaluation of adherence to concomitant therapy; Decrease in the percentage of patients adhering from both...

  • Relationship between the Frequency of Blood Pressure Self-Measurement and Blood Pressure Reduction with Antihypertensive Therapy: Results of the OLMETEL (OLMEsartan TELemonitoring Blood Pressure) Study. Ewald, Silke; vor dem Esche, Johannes; Uen, Sakir; Neikes, Fabian; Vetter, Hans; Mengden, Thomas // Clinical Drug Investigation;2006, Vol. 26 Issue 8, p439 

    OBJECTIVES: This subanalysis of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study in patients with essential hypertension assessed the relationship between the frequency of blood pressure self-measurement (BPSM) and the response to blood pressure (BP)-lowering therapy with olmesartan...

  • Safety and tolerability of moxonidine in the treatment of hypertension. Schachter, M.; Luszick, J.; Jäger, B.; Verboom, C.; Söhlke, E.; Jäger, B; Söhlke, E // Drug Safety;Sep1998, Vol. 19 Issue 3, p191 

    Classical centrally acting antihypertensive agents lower blood pressure by reducing excessive sympathetic tone; however, their clinical use is limited by an adverse effect profile resulting from α-adrenoceptor agonism. Moxonidine is a new centrally acting agent showing selective agonism of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics